Supplementary Tables S1-S3 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Table S1: Representativeness of Study Participants.Supplementary Table S2: Immunogenicity in patients treated with FS118.Supplementary Table S3: PK of FS118 by Dose Level.
Authors: Timothy A. Yap, Patricia M. LoRusso, Deborah J. Wong, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leung, Sylwia Marshall, Claire S. Reader, Roslin Russell, Richard C.A. Sainson, Claire J. Seal, Christopher J. Shepherd, Fiona Germaschewski, Daniel Gliddon, Omer Stern, Lesley Young, Neil Brewis, Louis Kayitalire, Michelle Morrow
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416628813
Cites:
Cited by:
Related to: